FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4315706179> ?p ?o ?g. }

• W4315706179 endingPage "39" @default.
• W4315706179 startingPage "35" @default.
• W4315706179 abstract "Background. Radiation therapy for locally advanced nasopharyngeal carcinoma (NC) has a high incidence of fatal complications, which leads to absolute contraindications to External Beam Radiation Therapy (EBRT). Chemoembolization of a nasopharyngeal tumor significantly reduces these risks and allows for EBRT. The aim of this study was to assess response rate after chemoembolization and EBRT. Objective. To evaluate the response rate in patients with locally advanced nasopharyngeal cancer treated with chemoembolization of tumor vessels and external beam radiation therapy in combination with chemotherapy. Methods. Prospective descriptive study was conducted. Patients with cT3–4, N0–2, M0 NC treated in April 2016 – March 2021 were enrolled. All patients had chemoembolization with doxorubicin’s microspheres followed by EBRT administrated once daily (2,0 Gy per fraction). Treatment response rate was assessed according RECIST 1.1 criteria in three weeks. Results. Twenty-one patients were identified. The median age was 47 years (IQR: 20–60). Tumors were staged as cT3N0M0 in 1 (4.8%) case, cT3N1M0 in 6 (28.6%) cases, cT3N2M0 in 5 (23.8%) cases, cT4N0M0 in 1 (4.8%) case, cT4N1M0 in 1 (4.8%) case and cT4N2M0 in 7 (33.4%) cases. There were the following histopathology types of NC: WHO type I (n = 1), WHO type II (n = 7) and WHO type III (n = 13). Fourteen (66.7%) patients had EBV-non-associated tumor and 7 patients were EBV-associated. Twenty (95.2%) patients had absolute contraindications to EBRT. All patients had chemoembolization. Complete response (CR) after chemoembolization was achieved in 3 (14.3%) patients, partial response (PR) was in 4 (19%) patients, stabilization was in 12 (57.1%), and progression was in 2 (9.6%) patients. All 21 patients had EBRT (median total dose 66 Gy [IQR: 60–72]).CR after EBRT was achieved in 17 (80%) patients and progression was in 4 (20%) patients. Conclusions. Chemoembolization provides acceptable response rate in patients with locally advanced NC and allows for EBRT. Further studies are needed to evaluate local control." @default.
• W4315706179 created "2023-01-12" @default.
• W4315706179 creator A5049528463 @default.
• W4315706179 creator A5050033074 @default.
• W4315706179 creator A5056660825 @default.
• W4315706179 creator A5059472264 @default.
• W4315706179 date "2023-01-11" @default.
• W4315706179 modified "2023-09-30" @default.
• W4315706179 title "Results of treatment of patients with nasopharyngeal cancer after superselective chemoembolization of tumor vessels" @default.
• W4315706179 cites W1990385229 @default.
• W4315706179 cites W2014852128 @default.
• W4315706179 cites W2075324122 @default.
• W4315706179 cites W2125795439 @default.
• W4315706179 cites W2125919881 @default.
• W4315706179 cites W2156838333 @default.
• W4315706179 cites W2320101695 @default.
• W4315706179 cites W2889646458 @default.
• W4315706179 doi "https://doi.org/10.33667/2078-5631-2022-31-35-39" @default.
• W4315706179 hasPublicationYear "2023" @default.
• W4315706179 type Work @default.
• W4315706179 citedByCount "0" @default.
• W4315706179 crossrefType "journal-article" @default.
• W4315706179 hasAuthorship W4315706179A5049528463 @default.
• W4315706179 hasAuthorship W4315706179A5050033074 @default.
• W4315706179 hasAuthorship W4315706179A5056660825 @default.
• W4315706179 hasAuthorship W4315706179A5059472264 @default.
• W4315706179 hasBestOaLocation W43157061791 @default.
• W4315706179 hasConcept C120665830 @default.
• W4315706179 hasConcept C121332964 @default.
• W4315706179 hasConcept C126322002 @default.
• W4315706179 hasConcept C126838900 @default.
• W4315706179 hasConcept C141071460 @default.
• W4315706179 hasConcept C188816634 @default.
• W4315706179 hasConcept C2775908122 @default.
• W4315706179 hasConcept C2776694085 @default.
• W4315706179 hasConcept C2777416452 @default.
• W4315706179 hasConcept C2778822529 @default.
• W4315706179 hasConcept C2778997737 @default.
• W4315706179 hasConcept C2779984678 @default.
• W4315706179 hasConcept C509974204 @default.
• W4315706179 hasConcept C61511704 @default.
• W4315706179 hasConcept C71924100 @default.
• W4315706179 hasConceptScore W4315706179C120665830 @default.
• W4315706179 hasConceptScore W4315706179C121332964 @default.
• W4315706179 hasConceptScore W4315706179C126322002 @default.
• W4315706179 hasConceptScore W4315706179C126838900 @default.
• W4315706179 hasConceptScore W4315706179C141071460 @default.
• W4315706179 hasConceptScore W4315706179C188816634 @default.
• W4315706179 hasConceptScore W4315706179C2775908122 @default.
• W4315706179 hasConceptScore W4315706179C2776694085 @default.
• W4315706179 hasConceptScore W4315706179C2777416452 @default.
• W4315706179 hasConceptScore W4315706179C2778822529 @default.
• W4315706179 hasConceptScore W4315706179C2778997737 @default.
• W4315706179 hasConceptScore W4315706179C2779984678 @default.
• W4315706179 hasConceptScore W4315706179C509974204 @default.
• W4315706179 hasConceptScore W4315706179C61511704 @default.
• W4315706179 hasConceptScore W4315706179C71924100 @default.
• W4315706179 hasIssue "31" @default.
• W4315706179 hasLocation W43157061791 @default.
• W4315706179 hasOpenAccess W4315706179 @default.
• W4315706179 hasPrimaryLocation W43157061791 @default.
• W4315706179 hasRelatedWork W2358752229 @default.
• W4315706179 hasRelatedWork W2359948402 @default.
• W4315706179 hasRelatedWork W2363910323 @default.
• W4315706179 hasRelatedWork W2372838325 @default.
• W4315706179 hasRelatedWork W2375776487 @default.
• W4315706179 hasRelatedWork W2379282113 @default.
• W4315706179 hasRelatedWork W2379380436 @default.
• W4315706179 hasRelatedWork W2384200964 @default.
• W4315706179 hasRelatedWork W2387690194 @default.
• W4315706179 hasRelatedWork W2393154103 @default.
• W4315706179 isParatext "false" @default.
• W4315706179 isRetracted "false" @default.
• W4315706179 workType "article" @default.